We are advancing first-in-class Panx1 blockers with a disciplined development strategy—beginning in post-surgical neuropathic pain (PSNP) and expanding across multiple neuropathic pain indications.
Targeting Panx1 addresses a validated mechanism in generation and persistence of neuropathic pain.
A clear, efficient path designed to generate proof-of-concept and establish clinical value.
A differentiated mechanism with relevance across multiple forms of neuropathic pain.
From a focused entry to broad impact across neuropathic pain.
Chronic Post-Surgical Neuropathic Pain
Establish proof-of-concept, safety and tolerability.
Diabetic Neuropathy
Chemotherapy-Induced Neuropathy
Post-Herpetic Neuralgia
Additional Neuropathic Pain Indications
Grounded in strong biology and a clear clinical path, with expansion potential across neuropathic pain.